Antígenos parasitarios de O-Glicosilación incompleta: Un enfoque inmunoterapeutico contra el cáncer
Resumen
Palabras clave
Texto completo:
PDFReferencias
Abdel-Rahim A. Y. (2001). Parasitic infections and hepatic neoplasia. Dig. Dis. 19: 288-291.
Alvarez-Errico D., Medeiros A., Miguez M., Casaravilla C., Malgor R., Carmona C, et al. (2001). O-glycosylation in Echinococcus granulosus: identification and characterization of the carcinoma associated Tn antigen. Exp. Parasitol. 98: 100-109.
Ando H., Matsushita T., Wakitani M., Sato T., Kodama-Nishida S., Shibata K., et al. (2008). Mouse-human chimeric anti-Tn IgG1 induced anti-tumor activity against Jurkat cells in vitro and in vivo. Biol. Pharm. Bull. 31: 1739-1744.
Blixt O., Lavrova O. I., Mazurov D. V., Cló E., Kracun S. K., Bovin N. V., et al. (2012). Analysis of Tn
antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells. Glycobiology. 22: 529-542.
Bonfante-Cabarcas R., Ibarra A., Salas Y., Colmenares de Páez V., Bonfante-Rodríguez R., RodríguezBonfante C., et al. (2013). Trypanosoma cruzi inhibits the development of tumors in C57/BL6
mice and the growth of B16/BL6 melanoma cells in culture. Rev. Soc. Bras. Med. Trop. (En prensa).
Bouanene H., Sahrawi W., Mokni M., Fatma L. B., Bouriga A., Limen H. B., et al. (2011). Correlation between Heterogeneous Expression of Sialyltransferases and MUC16 in Ovarian Tumor Tissues. Onkologie. 34: 165-169.
Camby I., Le Mercier M., Lefranc F. & Kiss R. (2006). GalectiN-1: a small protein with major functions. Glycobiology. 16: 137-157.
Carlos C. A., Dong H. F., Howard O. M., Oppenheim J. J., Hanisch F. G. & Finn O. J. (2005). Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J. Immunol. 175: 1628-1635.
Casaravilla C., Freire T., Malgor R., Medeiros A., Osinaga E. & Carmona C. (2003). Mucin-type O glycosylation in helminth parasites from major taxonomic groups: evidence for widespread distribution of the Tn antigen (GalNAc-Ser/Thr) and identification of UDP-GalNAc: polypeptide N acetylgalactosaminyltransferase activity. J. Parasitol. 84: 709-714.
Casaravilla C. & Díaz A. (2010). Studies on the structural mucins of the Echinococcus granulosus laminated layer. Mol. Biochem. Parasitol. 174: 132-136.
Chapman P. B., Morrissey D. M., Panageas K. S., Hamilton W. B., Zhan C., Destro A. N., et al. (2000). Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin. Cancer. Res. 6: 874-879.
Dunn G. P., Bruce A. T., Ikeda H., Old L. J. & Schreiber R. D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
Dunn G. P., Old L. J. & Schreiber R. D. (2004). The three Es of cancer immunoediting. Annu. Rev. Immunol. 22: 329-360.
Freire T., Robello C., Casaravilla C., Errico D. A., Medeiros A., Carmona C, et al. (2002). Antígenos mucínicos de O-glicosilación simple: nuevas similitudes entre células cancerosas y parásitos. Actas. Fisiol. 8: 89-107.
Freire T. & Osinaga E. (2003a). Immunological and biomedical relevance of the Tn antigen. Rev. Immunol. 1: 27-38.
Freire T., Casaravilla C., Carmona C. & Osinaga E. (2003b). Mucin-type O-glycosylation in Fasciola hepatica: characterization of carcinomaassociated Tn and sialyl-Tn antigens and evaluation of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase activity. Int. J. Parasitol. 33: 47-56.
Freire T., Robello C., Soulé S., Ferreira F. & Osinaga E. (2003c). Sialyl-Tn antigen expression and O-linked GalNAc-Thr synthesis by Trypanosoma cruzi. Biochem. Biophys. Res. Commun. 26: 1309-1316.
Freire T., Bay S., Vichier-Guerre S., LoMan R. & Leclerc C. (2006). Carbohydrate antigens: synthesis aspects and immunological applications in cancer. Mini. Rev. Med. Chem. 12: 1357-1373.
Freire T. & Osinaga E. (2012). The sweet side of tumor immunotherapy. Immunotherapy. 4: 719-734.
Gallegos V., Itandehui B., Coutiño R., Martínez G. & Hernández-Cruz P. (2008). Marcadores glicosilados en cáncer de mama. REB. 27: 52-59.
Galli-Stampino L., Meinjohanns E., Frische K., Meldal M., Jensen T., Werdelin O., et al. (1997). T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer. Res. 57: 3214-3222.
García E. & Torrella A. (2004). Vacunas en melanoma. Oncología. 27: 108-113.
Gilewski T. A., Ragupathi G., Dickler M., Powell S., Bhuta S., Panageas K., et al. (2007). Immunization
of high risk breast cancer patients with clustered sTN-KLH conjugateplus the immunologic adjuvant QS-21. Clin. Cancer. Res. 13: 2977-2985.
Glinsky V. V., Glinsky G. V., Glinskii O. V., Huxley V. H., Turk J. R., Mossine V. V., et al. (2003). Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer. Res. 63: 3805-3811.
Gong P., Zhang J., Cao L., Nan Z., Li Z., Yang J., et al. (2011). Identification and characterization of myeloma-associated antigens in Trichinella spiralis. Exp. Parasitol. 4: 784-788.
Gruszewska E. & Chrostek L. (2013). The alterations of glycosylation in malignant diseases. Pol. Merkur. Lekarski. 34: 58-61.
Hanisch F. G. & Ninkovic T. (2006). Immunology of O-glycosylated proteins: approaches to the design
of a MUC1 glycopeptide-based tumor vaccine. Cur. Protein. Pept. Sci. 7: 307-315.
Hill M., Mazal D., Biron V. A., Pereira L., Ubillos L., Berriel E., et al. (2010). A novel clinically relevant
animal model for studying galectin-3 and its ligands during colon carcinogenesis. J. Histochem. Cytochem. 58: 553-565.
Hubert P., Heitzmann A., Viel S., Nicolas A., SastreGarau X., Oppezzo P., et al. (2011). Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer. Res. 71: 5134-5143.
Jeschke U., Mylonas I., Shabani N., Kunert-Keil C., Schindlbeck C., Gerber B., et al. (2005).
Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. Anticancer. Res. 25: 1615-1622.
Ju T., Lanneau G. S., Gautam T., Wang Y., Xia B., Stowell S. R., et al. (2008). Human tumor antigens
Tn and sialyl Tn arise from mutations in Cosmc. Cancer. Res. 68: 1636-1646.
Ju T., Otto VI. & Cummings RD. (2011). The Tn antigen-structural simplicity and biological complexity. Angew. Chem. Int. Ed. Engl. 50: 1770- 1791.
Julien S., Lagadec C., Krzewinski-Recchi M. A., Courtand G., Le Bourhis X. & Delannoy P. (2005).
Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration. Breast. Cancer. Res. Treat. 90: 77-84.
Julien S., Picco G., Sewell R., Vercoutter-Edouart A. S., Tarp M., Miles D., et al. (2009). SialylTn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br. J. Cancer. 100: 1746-1754.
Kowalczyk W., Monsó M., de la Torre B. G., & Andreu D. (2011). Synthesis of multiple antigenic
peptides (MAPs)-strategies and limitations. J. Pept. Sci. 4: 247-251.
Kuduk S., Schwarz J., Chen X. T., Glunz P., Sames D., Ragupathi G., et al. (1998). Synthetic and
immunological studies of clustered modes of muciN-related Tn and TF O-linked antigens: the preparation of a glycopeptide-based vaccines for clinical trials against prostate cancer. J. Am. Chem. Soc. 120: 12474-12485.
Kurtenkov O., Miljukhina L., Smorodin J., Klaamas K., Bovin N., Ellamaa M., et al. (1999). Natural
IgM and IgG antibodies to Thomsen-Friedenreich (T) antigen in serum of patients with gastric cancer
and blood donors--relation to Lewis (a,b) histoblood group phenotype. Acta. Oncol. 38: 939-943.
Lauwaet T., Oliveira M., Mareel M. & Leroy A. (2000). Molecular mechanisms of invasion by cancer cells, leukocytes and microorganisms. Microbes. And. Infection. 2: 923-931. Lisowska E. (2002). The role of glycosylation in protein antigenic properties. Cell. Mol. Life. Sci. 59: 445-455.
Lo-Man R., Bay S., Vichier-Guerre S., Deriaud E., Cantacuzene D. & Leclerc C. (1999). A fully synthetic immunogen carrying a carcinomaassociated carbohydrate for active specific immunotherapy. Cancer. Res. 59:1520-1524.
Lo-Man R., Vichier-Guerre S., Bay S., Deriaud E., Cantacuzene D. & Leclerc C. (2001). Antitumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J. Immunol. 166: 2849-2854. Maizels R. M., Balic A., Gomez-Escobar N., Nair
M., Taylor M. D. & Allen J. E. (2004). Helminth parasites-masters of regulation. Immuno. Rev. 201: 89-116.
Mathieu S., Prorok M., Benoliel A. M., Uch R., Langlet C., Bongrand P., et al. (2004). Transgene
expression of alpha(1,2)-fucosyltransferase-I (FUT1) in tumor cells selectively inhibits sialylLewis x expression and binding to E-selectin without affecting synthesis of sialyl-Lewis a or binding to P-selectin. Am. J. Pathol. 164: 371-383.
Mel’nikov V. G., Fierro Velasko F. H. & Dobrovinskaya O. R. (2004). Suppression of growth and metastasizing of T-cell lymphoma in mice infected with american trypanosomiasis at different stages of experimental infection. Bull. Exp. Biol. Med. 137: 475-478.
Mendes T. A., Lobo F. P., Rodrigues T. S., RodriguesLuiz G. F., Darocha W. D., Fujiwara R. T., et al. (2013). Repeat-enriched proteins are related to host cell invasion and immune evasion in parasitic protozoa. Mol. Biol. Evol. 30: 951-963.
Miles D., Roché H., Martin M., Perren T. J., Cameron D. A., Glaspy J., et al. (2011). Phase III multicenter
clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 16: 1092-1100.
Nguyen-Truong C. K., Lee-Lin F. & Gedaly-Duff V. (2013). Contributing factors to colorectal cancer and hepatitis B screening among vietnamese Americans. Oncol. Nurs. Forum. 40: 238-251.
Oliveira E. C., Leite M., Miranda J. A., Andrade A. L., Garcia S. B., Luquetti A. O., et al. (2001). Chronic
Trypanosoma cruzi infection associated with low incidence of 1,2 dimethylhydrazine induced colon cancer in rats. Carcinogenesis. 22: 737-740.
Ono M. & Hakomori S. (2004). Glycosylation defining cancer cell motility and invasiveness. Glycoconj. J. 20: 71-78.
Ostrand-Rosenberg S., Sinha P., Beury D. W. & Clements V. K. (2012). Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumorinduced immune suppression. Semin. Cancer. Biol. 22: 275-281.
Pérez-Aguilar M. C., Goncalves L., Mogollón N. & Bonfante-Cabarcas R. (2013). O-glicosilación
incompleta en células cancerígenas y parásitos: Importancia Biomédica. Salus. 17: 58-67.
Pérez-Victoria J., Di Pietro A., Barron D., Ravelo A., Castanys S. & Gamarro F. (2002). Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents. Curr. Drug. Targets. 3: 311-333.
Pinho S., Marcos N. T., Ferreira B., Carvalho A. S., Oliveira M. J., Santos-Silva F., et al. (2007). Biological significance of cancer-associated sialylTn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer. Lett. 249: 157-170.
Portela S. V., Martín C. V., Romay L. M., Cuevas E., Martín E. G. & Briera A. F. (2011). sLea and sLex expression in colorectal cancer: implications for tumourigenesis and disease prognosis. Histol. Histopathol. 26: 1305-1316.
Proudfoot O., Apostolopoulos V. & Pietersz G. A. (2007). Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. Mol. Pharm. 4: 58-72.
Quezada S. A., Peggs K. S., Simpson T. R. & Allison J. P. (2011). Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev. 241: 104-118. Racey C. S., Withrow D. R. & Gesink D. (2013). Selfcollected HPV Testing Improves Participation in Cervical Cancer Screening: A Systematic Review and Meta-analysis. Can. J. Public. Health. 104: 159-166.
Ragupathi G., Liu N. X., Musselli C., Powell S., Lloyd K. & Livingston P. O. (2005). Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J. Immunol. 174: 5706-5712.
Rodríguez-Bonfante C., Bonfante-Cabarcas R., Ibarra A., Pérez-Aguilar M. C. & Labrador G. (2008). La infección por Trypanosoma cruzi inhibe el desarrollo del melanoma maligno. Bol. Med. Post. 24: 71-78.
Rosete P. G., Atzín J. A., Saldaña A. K., Espinosa B., Urrea F. J., Vásquez N. A., et al. (2008). Comportamiento tumoral y glicosilación. Rev. Inst. Nal. Enf. Resp. Mex. 21: 280-287.
Ryan S. O., Turner M. S., Gariépy J. & Finn O. J. (2010). Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer. Res. 70: 5788-5796.
Schjoldager K. T. & Clausen H. (2012). Site-specific protein O-glycosylation modulates proprotein processing-deciphering specific functions of the large polypeptide GalNAc-transferase gene family. Biochim. Biophys. Acta. 12: 2079-2094.
Schreiber R. D., Old L. J. & Smyth M. J. (2011). Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 331: 1565-1570.
Shurin G. V., Shurin M. R., Bykovskaia S., Shogan J., Lotze M. T. & Barksdale E. M. Jr. (2001). Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer. Res. 61: 363-369.
Tang X., Wu Y., Belenkaya TY., Huang Q., Ray L., Qu J. (2012). Roles of N- glycosylation and lipidation in Wg secretion and signaling. Dev. Biol. 364: 32-41.
Thurin M. & Kieber-Emmons T. (2002). SA-Lea and tumor metastasis: the old prediction and recent
findings. Hybrid. Hybridomics. 21: 111-116.
Thors C., Jansson B., Helin H. & Linder E. (2006). Thomsen-Friedenreich oncofetal antigen
in Schistosoma mansoni: localization and immunogenicity in experimental mouse infection. Parasitology. 132: 73-81.
Tuma R. S. (2011). Immunotherapies in clinical trials: do they demand different evaluation tools? J. Natl. Cancer. Inst. 103: 780-781.
Varki A., Etzler M. E., Cummings R. D., & Esko J. D. (2009). Discovery and Classification of GlycanBinding Proteins. En: Essentials of Glycobiology. 2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press. USA.
von Delwig A., Altmann D. M., Isaacs J. D., Harding C. V., Holmdahl R., McKie N., et al. (2006). The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model. Arthritis. Rheum. 54: 482-491.
Wakefield L. M. & Hill C. S. (2013). Beyond TGFβ: roles of other TGFβ superfamily members in cancer. Nat. Rev. Cancer. 13: 328-341.
Watanapa P. & Watanapa W. B. (2002). Liver flukeassociated cholangiocarcinoma. Br. J. Surg. 89: 962-970.
Wright M., Henkle K. & Mitchell G. (1990). An immunogenic Mr 23,000 integral membrane protein of Schistosoma mansoni worms that closely resembles a human tumor associated antigen. J. Immunol. 144: 3195-3200.
Xu Y., Gendler S. J. & Franco A. (2004). Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J. Exp. Med. 199: 707-716.
Yokoigawa N., Takeuchi N., Toda M., Inoue M., Kaibori M., Yanagida H., et al. (2007). Overproduction of PGE2 in peripheral blood monocytes of gastrointestinal cancer patients with mucins in their bloodstream. Cancer. Lett. 245: 149-155.
Zambrano-Villa S., Rosales-Borjas D., Carrero J. C. & Ortiz-Ortiz L. (2002). How protozoan parasites evade the immune response. Trends. Parasitol. 18: 272-278.
Zhang J., Yang J., Han X., Zhao Z., Du L., Yu T., et al. (2012). Overexpression of heparanase multiple
antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy. Oncol lett. 4: 178-182.
Zhu S., Sun P., Zhang Y., Yan L. & Luo B. (2013). Expression of c-myc and PCNA in EpsteiN-Barr virus-associated gastric carcinoma. Exp. Ther. Med. 5: 1030-1034.
Enlaces refback
- No hay ningún enlace refback.
Copyright (c) 2021 Boletín de Malariología y Salud Ambiental